Novartis (NOTA) Price & Analysis

Compare

19 Followers

NOTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range€88.20 - €110.50

Previous CloseN/A

Volume500.00

Average Volume (3M)18.00

Market Cap

€212.11B

Enterprise Value€262.89B

Total Cash (Recent Filing)€7.00B

Total Debt (Recent Filing)€32.64B

Price to Earnings (P/E)17.0

Beta0.39

Next Earnings

Oct 28, 2025

EPS Estimate

1.93

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.08

Shares Outstanding2,112,421,900

10 Day Avg. Volume10

30 Day Avg. Volume18

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€88.32

Price Target Upside-18.60% Downside

Rating ConsensusHold

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceIncreased cash on the balance sheet has led to a modestly higher target price for Novartis.

Product ApprovalCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.

Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.

Bears Say

Revenue ExpectationsThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.

Novartis News

Trump signs memorandum mandating pharma ads give more info on risks

U.S. President Donald Trump has signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding...

8h ago

AZN

BMY

Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz

Stocks were mostly unchanged near noon as the market rally stalls following last week’s move to record highs....

15h ago

Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio

Novartis ($NVS), the Swiss pharma giant, said on Tuesday it will acquire Tourmaline Bio ($TRML) for $48 per...

20h ago

NVS

TRML

Tourmaline Bio to be acquired by Novartis for $48.00 per share in cash

Tourmaline Bio (TRML) announced that it has entered into a merger agreement with Novartis (NVS), pursuant to which...

22h ago

NVS

TRML

Novartis price target raised to CHF 105 from CHF 100 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to CHF 105 from CHF...

2d ago

NVS

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, awards, collaborations, and more make up the biggest stock market stories for Wednesday. ...

6d ago

CRM

Novartis Stock (NVS) Beats Harder on $5.2B Chinese Heart Disease Deal

Shares in Swiss drugmaking giant Novartis ($NVS) were looking perkier today after it sealed a $5.2 billion deal...

6d ago

NVS

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

Oppenheimer analyst Matthew Biegler says the firm had a chance to speak with Olema Oncology (OLMA) management after...

7d ago

NVS

PFE

Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis

Arrowhead’s ($ARWR) stock jumped over 16% higher on Tuesday to $25.68 after the American biopharma company announced a...

7d ago

NVS

ARWR

Argo announces new strategic collaboration with Novartis

Argo Biopharmaceutical announced that it has entered into an additional strategic collaboration with Novartis (NVS) for multiple cardiovascular...

7d ago

NVS

Arrowhead, Novartis announce licensing and collaboration agreement for ARO-SNCA

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Novartis (NVS) for ARO-SNCA, Arrowhead’s preclinical stage siRNA...

8d ago

NVS

ARWR

Novartis’ Leqvio shows statistically significant LDL-C goal achievement in study

Novartis (NVS) announced “positive” results from V-DIFFERENCE, a Phase IV study evaluating Leqvio compared to placebo, both administered...

10d ago

NVS

Novartis, BioArctic enter collaboration and license pact for BrainTransporter

BioArctic announced that the company has entered into an option, collaboration and license agreement with Novartis (NVS) Pharma...

15d ago

NVS

Novartis price target raised to CHF 120 from CHF 115 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Novartis (NVS) to CHF 120 from CHF 115 and keeps...

20d ago

NVS

NOTA FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was €88.20 and its highest was €110.50 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is €212.11B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Oct 28, 2025 which is in 48 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Jul 17, 2025. The company reported €2.076 earnings per share for the quarter, beating the consensus estimate of €2.017 by €0.059.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.93.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of €2.076 in its last earnings report, beating expectations of €2.017. Following the earnings report the stock price went up 3.483%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in DE:NOTA

Novartis Stock Smart Score

Neutral

Fundamentals

Return on Equity

32.82%

Trailing 12-Months

Asset Growth

7.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis (NOTA) Earnings & Revenues

Historic Earnings Reports

NOTA Company Deck

NOTA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a generally positive outlook for Novartis, with strong sales and income growth driven by key products like Kisqali, Kesimpta, and Pluvicto. The initiation of a new share buyback program further underscores confidence in future performance. However, challenges such as the slowing growth of Cosentyx and market slowdown in China present hurdles that the company will need to address.View all DE:NOTA earnings summaries

NOTA Stock 12 Month Forecast

Average Price Target

€88.32

▼(-18.60% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"€83","104":"€104","88.25":"€88.3","93.5":"€93.5","98.75":"€98.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91.71631836,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€91.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.31941768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€88.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.922517,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€84.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,88.25,93.5,98.75,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.2,94.93202448923077,94.66404897846154,94.3960734676923,94.12809795692309,93.86012244615385,93.59214693538462,93.32417142461539,93.05619591384615,92.78822040307692,92.5202448923077,92.25226938153847,91.98429387076924,{"y":91.71631836,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.2,94.67072443692308,94.14144887384616,93.61217331076924,93.08289774769231,92.55362218461539,92.02434662153847,91.49507105846153,90.96579549538461,90.43651993230769,89.90724436923077,89.37796880615385,88.84869324307692,{"y":88.31941768,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.2,94.40942438461539,93.61884876923077,92.82827315384615,92.03769753846154,91.24712192307692,90.4565463076923,89.6659706923077,88.87539507692308,88.08481946153846,87.29424384615385,86.50366823076924,85.71309261538461,{"y":84.922517,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":97.992,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.813,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.992,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.081,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.245,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.454,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.992,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.447,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >